Figures & data
Table 1 Characteristics of included studies
Table 2 Risk of bias in the retrospective study
Figure 2 Graph of the bias risk of the enrolled RCTs.
Abbreviation: RCT, randomized controlled trail.
![Figure 2 Graph of the bias risk of the enrolled RCTs.](/cms/asset/5ad2c76d-7b0d-4c51-add7-b2e1aef9c64b/dcop_a_181246_f0002_c.jpg)
Figure 3 Forest plot and meta-analysis of the total number of patients with one or more exacerbations treated with macrolides compared with the control.
Abbreviation: M–H, Mantel–Haenszel method.
![Figure 3 Forest plot and meta-analysis of the total number of patients with one or more exacerbations treated with macrolides compared with the control.Abbreviation: M–H, Mantel–Haenszel method.](/cms/asset/08b5131b-58b7-4d9d-b8ce-23445126a2da/dcop_a_181246_f0003_b.jpg)
Figure 4 Forest plot and subgroup analyses of the total number of patients with one or more exacerbations treated with macrolides compared with the control: (A) different types of macrolides and (B) different durations of treatment.
![Figure 4 Forest plot and subgroup analyses of the total number of patients with one or more exacerbations treated with macrolides compared with the control: (A) different types of macrolides and (B) different durations of treatment.](/cms/asset/06ef3e9f-d304-45e7-93e1-67df2c07339c/dcop_a_181246_f0004_b.jpg)
Figure 5 Forest plot and meta-analysis of risk ratios for exacerbations per patient per year treated with macrolides compared with the control.
![Figure 5 Forest plot and meta-analysis of risk ratios for exacerbations per patient per year treated with macrolides compared with the control.](/cms/asset/24f4f3ec-eb48-440c-a733-426a97e780b3/dcop_a_181246_f0005_b.jpg)
Figure 6 Forest plot and meta-analysis of the total number of patients requiring hospitalization treated with macrolides compared with the control.
![Figure 6 Forest plot and meta-analysis of the total number of patients requiring hospitalization treated with macrolides compared with the control.](/cms/asset/ef135e58-9681-4d60-9214-ee40e6ab2cca/dcop_a_181246_f0006_c.jpg)
Figure 7 Forest plot and meta-analysis of the mean differences in change in total SGRQ score among patients treated with macrolides compared with the control.
![Figure 7 Forest plot and meta-analysis of the mean differences in change in total SGRQ score among patients treated with macrolides compared with the control.](/cms/asset/4a646d55-721c-4853-b9e6-3701068a3d05/dcop_a_181246_f0007_b.jpg)
Figure 8 Forest plot and meta-analysis of the total number of patients who experienced adverse events during follow-up after treatment with macrolides compared with the control.
Abbreviation: M–H, Mantel–Haenszel method.
![Figure 8 Forest plot and meta-analysis of the total number of patients who experienced adverse events during follow-up after treatment with macrolides compared with the control.Abbreviation: M–H, Mantel–Haenszel method.](/cms/asset/685efb1e-5b20-4479-b4a7-001bca15688b/dcop_a_181246_f0008_c.jpg)
Figure 9 Forest plot and subgroup analyses of the total number of patients who experienced adverse events during follow-up after treatment with macrolides compared with the control: (A) different types of macrolides and (B) different durations of treatment.
![Figure 9 Forest plot and subgroup analyses of the total number of patients who experienced adverse events during follow-up after treatment with macrolides compared with the control: (A) different types of macrolides and (B) different durations of treatment.](/cms/asset/4de02517-f99e-4a0a-a039-e1a488928664/dcop_a_181246_f0009_c.jpg)
![Figure 9 Forest plot and subgroup analyses of the total number of patients who experienced adverse events during follow-up after treatment with macrolides compared with the control: (A) different types of macrolides and (B) different durations of treatment.](/cms/asset/015f2303-978b-48c7-bf7a-f3d6fdece37d/dcop_a_181246_f0009a_c.jpg)
Figure 10 Funnel plots illustrating meta-analysis of the total number of patients with one or more exacerbations after treatment with macrolides compared with the control.
![Figure 10 Funnel plots illustrating meta-analysis of the total number of patients with one or more exacerbations after treatment with macrolides compared with the control.](/cms/asset/60ea3b7f-9585-4594-ade9-9487d92cdab3/dcop_a_181246_f0010_c.jpg)
Figure S1 Sensitivity analyses of the total number of patients with one or more exacerbations treated with macrolides compared with the control.
Abbreviation: M–H, Mantel–Haenszel method.
![Figure S1 Sensitivity analyses of the total number of patients with one or more exacerbations treated with macrolides compared with the control.Abbreviation: M–H, Mantel–Haenszel method.](/cms/asset/d5d27fd5-49e3-4e7f-a9cd-70af18404be4/dcop_a_181246_sf0001_b.jpg)
Figure S2 Sensitivity analyses of risk ratios for exacerbations per patient per year treated with macrolides compared with the control.
![Figure S2 Sensitivity analyses of risk ratios for exacerbations per patient per year treated with macrolides compared with the control.](/cms/asset/a738db38-8fec-4460-8c66-fa3f890eb3ea/dcop_a_181246_sf0002_b.jpg)
Figure S3 Sensitivity analyses of the total number of patients requiring hospitalization treated with macrolides compared with the control.
Abbreviation: M–H, Mantel–Haenszel method.
![Figure S3 Sensitivity analyses of the total number of patients requiring hospitalization treated with macrolides compared with the control.Abbreviation: M–H, Mantel–Haenszel method.](/cms/asset/75653376-1b72-4617-a3ab-80b93305e974/dcop_a_181246_sf0003_c.jpg)
Figure S4 Sensitivity analyses of the mean differences with respect to change in total SGRQ score among patients treated with macrolides compared with the control.
Abbreviation: SGRQ, St George Respiratory Questionnaire.
![Figure S4 Sensitivity analyses of the mean differences with respect to change in total SGRQ score among patients treated with macrolides compared with the control.Abbreviation: SGRQ, St George Respiratory Questionnaire.](/cms/asset/c5f00da8-13d2-4839-aac8-efc293f739b5/dcop_a_181246_sf0004_b.jpg)
Figure S5 Sensitivity analyses of the total number of patients who experienced adverse events during follow-up after treatment with macrolides compared with the control.
Abbreviation: M–H, Mantel–Haenszel method.
![Figure S5 Sensitivity analyses of the total number of patients who experienced adverse events during follow-up after treatment with macrolides compared with the control.Abbreviation: M–H, Mantel–Haenszel method.](/cms/asset/dcc23b1e-7895-4b44-afe1-f5262c9bbb59/dcop_a_181246_sf0005_c.jpg)
Table S1 Sensitivity analyses of subgroup based on the number of patients with exacerbations and adverse effects